After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

Vertex sees 2025 revenue of $11.75 billion to $12.0 billion, the midpoint of which is above analysts' average expectation of ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

The drugmaker is looking to its acute pain drug, Journavx, to drive growth beyond its established line of cystic fibrosis treatments. Vertex expects to begin shipping Journavx to pharmacies in the ...

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...

One of the most significant news items involving Vertex isn't reflected in the company's numbers just yet. Vertex's non-opioid pain relief drug, Journavx, received FDA approval on Jan. 30. The drug is ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

The media goes wild. This time around, the media is making a fuss about Vertex Pharmaceuticals Incorporated’s suzetrigine, a newly FDA-approved painkiller that also goes by the equally ...